**Core Concept**
Voglibose is an alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus. It works by delaying carbohydrate absorption in the gut, thereby reducing postprandial glucose levels.

**Why the Correct Answer is Right**
Voglibose specifically inhibits intestinal alpha-glucosidases, which are enzymes responsible for breaking down disaccharides and oligosaccharides into monosaccharides. By inhibiting these enzymes, voglibose slows down the digestion and absorption of carbohydrates, leading to a decrease in postprandial glucose levels. This mechanism helps in reducing the glucose load on the body, making it easier to manage blood sugar levels in patients with type 2 diabetes.

**Why Each Wrong Option is Incorrect**
**Option A:** Voglibose is not a sulfonylurea, which is a class of medications that stimulate insulin release from the pancreas. Voglibose's mechanism is distinct from sulfonylureas.
**Option B:** Voglibose is not an insulin sensitizer, which is a class of medications that improve insulin sensitivity in the body. Voglibose works by delaying carbohydrate absorption, rather than improving insulin sensitivity.
**Option C:** Voglibose is actually a correct statement regarding voglibose. It is indeed used to manage postprandial hyperglycemia in patients with type 2 diabetes.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that alpha-glucosidase inhibitors like voglibose are most effective when used in conjunction with dietary modifications and other antidiabetic medications to achieve optimal glycemic control.

**Correct Answer:** B. Voglibose is not an insulin sensitizer.